NASDAQ:BCYC - Bicycle Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.00
  • Forecasted Upside: 37.60 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$31.25
▲ +1.83 (6.22%)

This chart shows the closing price for BCYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bicycle Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCYC

Analyst Price Target is $43.00
▲ +37.60% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $43.00, with a high forecast of $58.00 and a low forecast of $25.00. The average price target represents a 37.60% upside from the last price of $31.25.

This chart shows the closing price for BCYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Bicycle Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021OppenheimerBoost Price Target$38.00 ➝ $44.00Low
5/7/2021HC WainwrightBoost Price TargetBuy$31.00 ➝ $39.00Low
5/7/2021Piper SandlerBoost Price TargetOverweight$35.00 ➝ $39.00Low
4/20/2021JMP SecuritiesInitiated CoverageOutperform$53.00Medium
1/20/2021Cantor FitzgeraldBoost Price TargetOverweight$30.00 ➝ $58.00Medium
1/15/2021OppenheimerBoost Price TargetOutperform$27.00 ➝ $38.00High
1/15/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $31.00N/A
12/3/2020HC WainwrightReiterated RatingBuy$28.00High
10/12/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00Low
9/22/2020OppenheimerReiterated RatingBuy$27.00High
9/10/2020Canaccord GenuityBoost Price TargetBuy$23.50 ➝ $25.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$25.00Low
7/21/2020OppenheimerReiterated RatingBuy$27.00High
6/24/2020OppenheimerReiterated RatingBuy$27.00Low
6/11/2020OppenheimerInitiated CoverageOutperform$27.00High
5/12/2020Canaccord GenuityReiterated RatingBuy$23.50Low
5/8/2020HC WainwrightReiterated RatingBuy$25.00High
4/17/2020HC WainwrightInitiated CoverageBuy$25.00Low
3/12/2020Canaccord GenuityInitiated CoverageBuy$23.50High
11/14/2019Roth CapitalInitiated CoverageBuy$17.00 ➝ $17.00High
9/30/2019Canaccord GenuitySet Price TargetBuy$22.00High
9/11/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$14.00High
6/17/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
6/17/2019The Goldman Sachs GroupInitiated CoverageNeutralLow
6/17/2019Piper Jaffray CompaniesInitiated CoverageOverweight$20.00Low
6/17/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$22.00Medium
(Data available from 6/24/2016 forward)
Bicycle Therapeutics logo
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $31.25
Low: $29.41
High: $31.36

50 Day Range

MA: $30.23
Low: $28.10
High: $32.13

52 Week Range

Now: $31.25
Low: $15.20
High: $33.20

Volume

67,985 shs

Average Volume

135,899 shs

Market Capitalization

$752.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicycle Therapeutics?

The following Wall Street analysts have issued reports on Bicycle Therapeutics in the last year: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for BCYC.

What is the current price target for Bicycle Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Bicycle Therapeutics in the last year. Their average twelve-month price target is $43.00, suggesting a possible upside of 46.2%. Cantor Fitzgerald has the highest price target set, predicting BCYC will reach $58.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $25.00 for Bicycle Therapeutics in the next year.
View the latest price targets for BCYC.

What is the current consensus analyst rating for Bicycle Therapeutics?

Bicycle Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCYC will outperform the market and that investors should add to their positions of Bicycle Therapeutics.
View the latest ratings for BCYC.

What other companies compete with Bicycle Therapeutics?

How do I contact Bicycle Therapeutics' investor relations team?

Bicycle Therapeutics' physical mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company's listed phone number is 441223261503. The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.